Every 10-Q that Gossamer Bio (GOSS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GOSS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOSS filings page.
Gossamer Bio, Inc. reported six‑month 2026 revenue of $26,193 (in thousands), entirely from its collaboration with Chiesi. Operating expenses were $97,133 (in thousands), leading to a loss from operations of $70,940 (in thousands). A $43,846 (in thousands) gain on extinguishment of 5.00% convertible notes drove second‑quarter net income of $16,900 (in thousands), but the company still recorded a six‑month net loss of $29,764 (in thousands).
Cash and cash equivalents were $41,148 (in thousands) and marketable securities $15,878 (in thousands) at June 30, 2026. Management states existing liquidity will fund operations only into the first quarter of 2027 and discloses substantial doubt about the ability to continue as a going concern. In June, Gossamer exchanged $181,052 (in thousands) of its 2027 notes for $65,174 (in thousands) of new 7.50% 2030 notes plus equity and warrants, leaving $18,948 (in thousands) of 2027 notes outstanding. The 2030 notes are classified as current because of a springing 2027 maturity. The company also reduced its workforce by 46%, recording $6.1 million in related charges, and later disclosed termination of the Chiesi collaboration, which had represented all revenue.
Gossamer Bio, Inc. reported first‑quarter 2026 revenue of $16.955 million, all from its collaboration with Chiesi, up from $9.889 million a year earlier. The company remains unprofitable, with a net loss of $46.664 million and an accumulated deficit of $1.4856 billion.
Cash, cash equivalents and marketable securities totaled about $99.2 million as of March 31, 2026, while total liabilities were $290.4 million, including $200 million of 5.00% convertible senior notes due 2027. Management states existing liquidity funds operations only into the first quarter of 2027 and raises substantial doubt about the company’s ability to continue as a going concern.
To cut expenses, Gossamer began a workforce reduction of 73 employees, roughly 46% of its staff, in March 2026, recording about $6.1 million in severance and related charges. The company continues to focus development on seralutinib for pulmonary arterial hypertension and PH‑ILD under its global collaboration with Chiesi.
Gossamer Bio (GOSS) reported Q3 2025 results, showing higher collaboration revenue but wider losses. Revenue was $13.3 million for the quarter, up from $9.5 million a year ago, driven by revenue from contracts with collaborators. For the nine months, revenue was $34.7 million versus $105.3 million last year, when results included $88.8 million of license revenue.
The company posted a Q3 net loss of $48.2 million (basic/diluted loss per share $0.21), compared with a $30.8 million loss a year earlier, as research and development expenses rose to $45.5 million. Year to date, operating cash flow was negative $123.0 million.
As of September 30, 2025, cash and cash equivalents were $8.9 million and marketable securities were $171.3 million. Total assets were $208.8 million against total liabilities of $291.2 million, resulting in a stockholders’ equity (deficit) of $(82.3) million. Long‑term convertible senior notes had a net carrying amount of $198.3 million. The company reports that Chiesi accounted for 100% of revenue during the nine‑month period under the collaboration agreement.